Connect your AI

Syndax Pharmaceuticals SNDX Price / sales

Price / sales at other companies

BiogenBIIB

2.7×+0.7×

IncyteINCY

3.5×+0.8×

AbbVieABBV

6.1×-0.3×

Viridian Therapeutics, Inc.VRDN

28.2×-3,609×

Nuvation BioNUVB

10.4×-44.0×

ImmunomeIMNM

616.2×+563×

Other financials

Income statement

Revenue$64.9M+224%

Operating income-$34.2M+59.2%

Net income-$42.7M+49.7%

EPS (diluted)-$0.48+51.0%

Balance sheet

Cash & equivalents$130.9M-15.0%

Total debt$350.5M+4.2%

Total equity$41.6M-80.6%

Total assets$472.7M-26.2%

Cash flow

Operating cash flow-$50.3M+47.1%

CapEx$46.8K—

Free cash flow-$80.8M-17.6%

Valuation

Market cap$1.74B+95.0%

Enterprise value$1.96B+84.0%

Profitability

Operating margin-102.8%-47.8pp

Net margin-111.9%-51.5pp

FCF margin-187.2%-85.4pp

Returns & leverage

Return on equity-189.5%-8,509pp

Debt / equity8.4×+6.9×

Current ratio5.5×-0.3×

Where this comes from

Calculated from Syndax Pharmaceuticals’s reported figures.

market cap/total revenue=9.5×

Based on the most recent quarter.

The official record: Syndax Pharmaceuticals’s 10-Q, filed April 30, 2026, on SEC EDGAR. View the filing →

Ask your AI about Syndax Pharmaceuticals's price / sales.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Harbor at dusk

Questions, answered.

What is Syndax Pharmaceuticals's price / sales?: Syndax Pharmaceuticals (SNDX) reported price / sales of 9.5× in Q1 2026.
How has Syndax Pharmaceuticals's price / sales changed year-over-year?: Syndax Pharmaceuticals's price / sales decreased by 60.8% year-over-year, from 24.2× to 9.5×.
What is the long-term trend for Syndax Pharmaceuticals's price / sales?: Over 3 years (2020 to 2025), Syndax Pharmaceuticals's price / sales has grown at a -76.3% compound annual growth rate (CAGR), from 791.2× to 10.6×.
What does price / sales mean?: Market capitalization at the quarter end divided by trailing-twelve-month revenue. The price the market pays for each dollar of sales.